If you have any question, please feel free to email us. We will touch with you as soon as possible.
For R&D purposes only. COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
* Please be kindly noted products are supplied for RLD supplies/ Reference listed drugs/ Comparator Drug Clinical trials. We do not sell to patients.
| Generic name | Trilaciclib for Injection |
| Trade name | Cosela |
| Specification | 300mg |
| Main ingredients | Trilaciclib |
| Dosage Form | Injection |
| MA Holder | G1 Therapeutics, Inc. |
| Category | Reference Listed Drugs (RLDs) |
Indications:
COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
For more details, pls contact Janney:
Email: tosun-global@upharm.cn
Wechat/Whatsapp:(+86)18922120575
Hot Tags: trilaciclib for injection reference listed drug, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bimatoprost Ophthalmic, Adefovir Dipivoxil Tablets, Alfacalcidol Soft Capsules, Acarbose Tablets, Reference Listed Drugs, AdapaleneGel
Tel:+86-020-61855200-902
Fax:+86-020-66392525
Email:info@upharm.cn
Address:12th floor, No. 181, Kexue Avenue, Huangpu District, Guangzhou, China
